Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2018 May;84(5) > Minerva Anestesiologica 2018 May;84(5):590-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Anestesiologica 2018 May;84(5):590-8

DOI: 10.23736/S0375-9393.18.12221-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Treatment of recent onset low back pain with periradicular injections of meloxicam: a randomized, double blind, placebo controlled cross-over study

Battista BORGHI 1, 2, Lucia AURINI 3 , Paul F. WHITE 3, 4, 5, 6, Andrea TOGNÙ 3, Barbara ROSSI 7, Greta FINI 2, Paola RUCCI 1, Tiziana GREGGI 8, Raffaele BORGHI 9

1 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; 2 Research Unit of Anaesthesia and Pain Therapy, Rizzoli Orthopedic Institute, Bologna, Italy; 3 Unit of Anesthesia and Pain Therapy, Rizzoli Orthopedic Institute, Bologna, Italy; 4 Department of Anesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA; 5 Department of Anesthesiology, Phoenix Thera-Lase, Dallas, TX, USA; 6 Department of Anesthesiology, the White Mountain Institute, The Sea Ranch, CA, USA; 7 Department of Medical and Surgical Sciences, Anesthesia, University of Bologna, Bologna, Italy; 8 Spine Deforming Surgery Division, Rizzoli Orthopedic Institute, Bologna, Italy; 9 2nd Orthopedic Clinic, Rizzoli Orthopedic Institute, Bologna, Italy


PDF


BACKGROUND: Low back pain (LBP) is a common and costly illness. This randomized, double-blind, placebo-controlled, cross-over study tested the hypothesis that periradicular injections of meloxicam would reduce LBP and improve physical activity compared to a saline injection at 3 months follow-up.
METHODS: After IRB approval, 80 consenting patients suffering LBP of <6 months duration were randomly assigned to the control (C-group, N.=40, receiving 10 mL of saline) or the meloxicam (M-group, N.=40, receiving 10 mg in 10 mL saline). If the pain Numeric Rating Score (NRS) at 24 hours remained >50% of the pretreatment score, the patient was crossed-over to the other group. A successful treatment was NRS<3 at 3 months follow-up. Secondary outcome measures which were assessed included work-absence, physical-assistance, physical-activities limitations and pain-related insomnia.
RESULTS: The baseline NRS was 9.3 (95% CI: 8.9-9.7) in the C-group and 9.2 (95% CI: 8.8-9.6) in the M-group. At the 24 hours follow-up after the initial treatment, the mean NRS was 6.3 (95% CI: 5.4-7.2) in the C-group vs. 3.5 (95% CI: 2.6-4.4) in the M-group (P<0.05). The number of cross-over cases was significantly higher in the C-group (N.=31, 77.5% vs. N.=5, 12.5%, P<0.001). At the 3 months follow-up, 66 patients (35+31) were allocated in the M-group and 54 (82%) reported NRS Score <3, while only 14 (9+5) patients remained in the C-group and eight patients had NRS<3.
CONCLUSIONS: Periradicular injection of meloxicam is an effective analgesic treatment for acute/subacute LBP. This novel use of meloxicam also leads to an improvement in the level of physical activity at the 3-month follow-up.


KEY WORDS: Low back pain - Injections - Meloxicam

top of page